VIMTALABS · Healthcare · Diagnostics & Research
Composite scorecard: 61/100 — Quality 81 · Valuation 24 · Momentum 74
| Share price | ₹530.25 |
| Market cap | ₹2,530 Cr |
| P/E ratio | 32.6 |
| P/B ratio | 5.5 |
| ROE | 21.4% |
| ROCE | 21.0% |
| Dividend yield | 0.35% |
| Book value | ₹102.28 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹407 Cr | ₹78 Cr | 26.2% |
| 2025 | ₹344 Cr | ₹67 Cr | 26.3% |
| 2024 | ₹318 Cr | ₹41 Cr | 27.0% |
| 2023 | ₹318 Cr | ₹48 Cr | 30.0% |
| 2022 | ₹278 Cr | ₹41 Cr | 29.0% |
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exp